RxDoctor Payments Data

Kelly Halcomb

Physician Assistant · Hamburg, NYNPI 1811933856

Payments from drug & device makers

$7,386in general payments, 2019–2025

Across 412 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$827
  • GSK$559
  • Pfizer$553
  • Amgen$470
  • Novo Nordisk$443
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$7,386100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,386 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$21,048
Medicare patients
169
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$123,064
TrulicityDulaglutide57$57,142
OzempicSemaglutide58$53,765
JardianceEmpagliflozin57$50,031
MounjaroTirzepatide23$26,716
Nurtec OdtRimegepant Sulfate14$23,956
Repatha SureclickEvolocumab27$21,512
MyrbetriqMirabegron19$21,064
XareltoRivaroxaban27$20,583
FarxigaDapagliflozin Propanediol20$20,091
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$18,745
JanumetSitagliptin Phos/Metformin Hcl14$15,118
TradjentaLinagliptin17$13,510
JanuviaSitagliptin Phosphate14$12,227
EntrestoSacubitril/Valsartan11$11,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$553$147,019133 claims
Lilly USA, LLCTrulicity, Mounjaro$1,126$83,85780 claims
Boehringer IngelheimJardiance, Tradjenta$827$63,54174 claims
Novo NordiskOzempic$443$53,76558 claims
MerckJanumet, Januvia$79$27,34528 claims
GSKTrelegy Ellipta, Breo Ellipta$559$27,07648 claims
Astellas Pharma US IncMyrbetriq$16$21,06419 claims
Johnson & JohnsonXarelto$16$20,58327 claims
AstraZenecaFarxiga$101$20,09120 claims
NovartisEntresto$167$11,07111 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$150$5,690347 claims
AbbVieSynthroid$251$5,44178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Hamburg

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →